Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246398 | 1.00 | XDH (0.52) | XDHADRB2SIGMAR1PYGLKDM4E | |
| Hydrochloric Acid SCHEMBL4599621 | 0.99 | XDH (0.51) | XDHADRB2SIGMAR1PYGLKDM4E | |
| SCHEMBL4600029 | 0.91 | XDH (0.49) | XDHADRB2PYGLKDM4ELMNA | |
| SCHEMBL4600036 | 0.91 | XDH (0.49) | XDHADRB2PYGLKDM4ELMNA | |
| Hydrochloric Acid SCHEMBL5351849 | 0.90 | XDH (0.48) | XDHADRB2PYGLKDM4ELMNA | |
| Hydrochloric Acid SCHEMBL5351844 | 0.90 | XDH (0.48) | XDHADRB2PYGLKDM4ELMNA | |
| SCHEMBL4598796 | 0.79 | XDH (0.58) | XDHPYGLKDM4ELMNATP53 | |
| Hydrochloric Acid SCHEMBL4599291 | 0.78 | XDH (0.57) | XDHPYGLKDM4ELMNATP53 | |
| SCHEMBL6517075 | 0.76 | KDM4E (0.63) | XDHKDM4ELMNAL3MBTL1MAPT | |
| SCHEMBL4426418 | 0.76 | SIGMAR1 (0.60) | SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556034-B1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| EP-1556034-B1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| US-7183294-B2 | Indole derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183294-B2 | Indole derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7138527-B2 | Inflammatory, allergic and respiratory disorders; beta 2 adrenoceptors agonists; such as 5-(-2-((-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl)amino)propyl) -N-(2-methoxybenzyl)-1H-indole-2-carboxamide | PFIZER INC. (US) | 2006-11-21 | — | — | US | disclosed |
| WO-2005092841-A1 | COMPOUNDS HAVING BETA-AGONIST ACTIVITY | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050085526-A1 | Indole derivatives useful for the treatment of diseases | BROWN ALAN D (GB) | 2005-04-21 | — | — | US | disclosed |
| US-6844362-B2 | Indole derivatives useful for the treatment of diseases | PFIZER INC (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1440966-A1 | Indole derivatives useful for the treatment of diseases | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20040116503-A1 | Indole derivatives useful for the treatment of diseases | PFIZER INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1407769-A1 | Indole derivatives as beta-2 agonists | Pfizer Limited (GB) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085526-A1 | Indole derivatives useful for the treatment of diseases | IDO1, IDO2, INMT | XDH 416/4885ADRB2 70/4885SIGMAR1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.